Xconomy National

Archives

by in

Entry	Author	Date	Location
Seattle Genetics Sees Case of PML, Causing Market Twitch	Luke Timmerman	12/01/11	Seattle
Immune Design, Developer of New Vaccines, Adds Former Elan President as New CEO	Luke Timmerman	04/27/11	Seattle
Biogen Shares Jump on Good News on Revenue, Oral MS Drug	Ryan McBride	04/21/11	Boston
Biogen Idec Passes Pivotal Trial With Oral MS Drug; Shares Climb	Luke Timmerman	04/11/11	Boston
FDA Wants More Data on Merck KGaA’s MS Pill As Biogen Develops Rival Therapy	Ryan McBride	03/02/11	Boston
Report: Layoffs Hit Elan	Wade Roush	01/26/11	San Francisco
Biogen Aims to Reduce PML Risk	Ryan McBride	12/22/10	Boston
Biogen Idec Buys Drug Rights from Neurimmune for $32.5M	Ryan McBride	12/21/10	Boston
Biogen Idec Chief Aims to Make Firm More Like Biotech and Less Like Pharma with Restructuring Plan	Ryan McBride	11/04/10	Boston
Biogen Idec Offering Jobs to Quarter of San Diego Workers, While Most Get Layoff Notices	Ryan McBride	11/03/10	Boston
Biogen Idec Axes 650 Jobs, Closes San Diego Site, Bets Future on Neurology	Luke Timmerman	11/03/10	Boston
Biogen Rival Reaches Finish Line with Oral Drug for MS	Ryan McBride	09/22/10	Boston
Arena Signs Deal With Eisai for Lorcaserin, Qualcomm CEO Identifies Two Opportunities in Mobile Health, & More San Diego Life Sciences News	Bruce V. Bigelow	07/08/10	San Diego
New CEO George Scangos Says Biogen Idec’s R&D Has to Improve	Ryan McBride	07/01/10	Boston
Chairman Bill Young: Next Biogen Idec CEO May Be a Scientist	Luke Timmerman	02/22/10	Boston
Tysabri’s PML Count Climbs to 28, and Some Reflections From Biogen Idec’s Departing CEO	Luke Timmerman	01/06/10	Boston
Biogen Idec CEO Jim Mullen Stepping Down, After Tumultuous Year of Shareholder Activism	Luke Timmerman	01/04/10	Boston
Facet Rejects Biogen’s Latest Offer	Rebecca Zacks	12/10/09	Boston
Biogen Fattens Offer to Buy Facet Biotech	Ryan McBride	12/03/09	Boston
Biogen Idec Accused Again of Excessive CEO Pay, Lousy Performance, By Big Shareholder	Luke Timmerman	11/20/09	Boston
Tysabri, the MS Drug Haunted by Deadly Side Effect, Doesn’t Look So Deadly Anymore	Luke Timmerman	11/19/09	Boston
Biogen Shares Drop as Tysabri PML Cases Climb to 23, Europe May Seek Drug ‘Holiday’	Luke Timmerman	10/23/09	Boston
Tysabri’s Tally of PML Cases Reaches 13	Luke Timmerman	09/17/09	Boston
Elan Breached Tysabri Partnership With Biogen Idec, Federal Judge Says	Luke Timmerman	09/04/09	Boston
Biogen Idec Faces Suit From Partner Elan, Genzyme Wins European Approval for Stem-Cell Boosting Drug, Alnylam Teams with Tekmira, & More Boston-Area Life Sciences News	Rebecca Zacks	08/12/09	Boston
Elan Hits Biogen Idec with Lawsuit to Protect Tysabri Deal with J&J	Ryan McBride	08/06/09	Boston
Biogen Gets Int’l Rights to Acorda’s MS Drug	Roxanne Palmer	07/01/09	Boston
Biogen Reports 10th PML Case in Tysabri Patient	Roxanne Palmer	06/29/09	Boston
Biogen Idec Showdown with Carl Icahn Culminates in Shareholder Vote Today	Luke Timmerman	06/03/09	Boston
Icahn’s Plan to Split Up Biogen Idec Would “Destroy Shareholder Value,” Company Says	Luke Timmerman	05/15/09	Boston
Page 1 of 3	next page »